Unicancer

This study tests whether the drug regorafenib can slow or stop the growth of bone sarcomas that have spread to other parts of the body. About 163 adults with advanced osteosarcoma, Ewing sarcoma, chondrosarcoma, or chordoma will receive either regorafenib or a placebo. The main g…

This study tests whether adding the drug tucatinib to two standard breast cancer treatments (pertuzumab and trastuzumab) can help people with HER2-positive breast cancer that has spread to the brain and is growing despite current therapy. About 53 adults whose cancer has progress…

This study looks at whether adding a high-dose, precise type of radiation called SBRT to usual treatments (like hormone therapy or chemo) can delay cancer progression in people with 1 to 5 bone metastases from breast, lung, or prostate cancer. About 168 adults aged 18-75 with goo…

This study looks at whether women aged 50 and older with a very low-risk type of early breast cancer (DCIS) can avoid radiation therapy after lumpectomy. The goal is to see if the cancer stays away without radiation, reducing unnecessary treatment and side effects. About 295 part…

This phase 3 trial tests whether adding radiation to a standard immunotherapy-plus-chemotherapy regimen can improve survival in people with advanced non-small cell lung cancer. About 327 participants with stage IIIB/IV disease will receive pembrolizumab and chemotherapy, with or …

This study is for people with a certain type of advanced breast cancer (HR+, HER2-low). First, a blood test looks for leftover cancer DNA after one month of standard hormone therapy and a CDK4/6 inhibitor. Those with positive results then receive trastuzumab deruxtecan, a targete…

This phase 3 study tests whether a hormone therapy plus abemaciclib works as well as chemotherapy for women with ER+/HER2- breast cancer that has spread to organs like the liver or lungs. About 180 participants will receive either standard chemo or the hormone combo. The goal is …

This study tests whether adding a precise type of radiation (stereotactic radiosurgery) to a three-drug combination (binimetinib, encorafenib, and pembrolizumab) can better control melanoma that has spread to the brain in people with a specific BRAF gene mutation. Ten adults with…

This study tests whether a drug called durvalumab can help frail patients with limited-stage small cell lung cancer keep their disease from getting worse after standard chemotherapy and radiation. About 100 participants who are older, have a weaker health status, or couldn't get …

This study is for people with muscle-invasive bladder cancer who cannot have their bladder removed due to age, health issues, or personal choice. After standard chemo-radiation, participants receive the drug atezolizumab to help keep the cancer from coming back. The goal is to co…

This trial tests whether adding the drug mifamurtide to standard chemotherapy after surgery helps people with high-risk osteosarcoma (a type of bone cancer) live longer without the cancer coming back. The study includes 60 patients aged 2 to 50 with newly diagnosed, aggressive os…

This large international study is testing whether a personalized breast cancer screening plan, based on each woman's individual risk, works better than the standard screening schedule. Over 53,000 women aged 40-70 are taking part. The goal is to see if the personalized approach c…

This study tests whether the drug riluzole can prevent nerve damage caused by oxaliplatin chemotherapy in people with stage II or III colorectal cancer. About 80 adults will receive either riluzole or a placebo during their chemotherapy. The goal is to see if riluzole reduces the…